| Business Summary | | Versicor
Incorporated
is
a
biopharmaceutical
company
focused
on
the
marketing,
development
and
discovery
of
pharmaceutical
products
for
the
treatment
of
bacterial
and
fungal
infections.
The
Company's
lead
product
candidate,
V-Echinocandin
(anidulafungin),
is
an
antifungal
intended
for
the
intravenous
treatment
of
serious
systemic
fungal
infections.
V-Echinocandin
has
potent
fungicidal
activity,
a
broad
spectrum
of
activity
against
candida
and
aspergillus,
low
potential
for
developing
resistance
and
a
novel
mechanism
of
action.
The
Company's
second
product
candidate,
V-Glycopeptide
(dalbavancin),
is
a
second
generation
antibiotic
belonging
to
the
same
class
as
Vancomycin
and
is
intended
for
the
treatment
of
serious
systemic
infections,
particularly
staphylococci.
V-Glycopeptide
has
potent
bactericidal
effect. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VERS
is
a
biopharmaceutical
company
focused
on
the
marketing,
development
and
discovery
of
pharmaceutical
products
for
the
treatment
of
bacterial
and
fungal
infections.
For
the
six
months
ended
6/30/01,
revenues
increased
17%
to
$3.3
million.
Net
loss
applicable
to
Common
increased
51%
to
$13.8
million.
Revenues
reflect
increased
collaborative
R&D
funding.
Net
loss
reflects
increased
R&D
expenses
due
to
an
increase
in
clinical
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Milligan, Ph.D., 60 Chairman | -- | -- | George Horner III, 56 Pres,
CEO, Director | $346K | -- | Richard White, Ph.D., 58 Exec.
VP, CSO | 438K | $540K | Timothy Henkel, M.D., Ph.D. Exec.
VP and CMO | -- | -- | Dov Goldstein, M.D., 32 VP-Fin.,
CFO | 111K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|